title: Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
abstract: Renal dysfunction and urinary abnormalities, which are usually related to drug toxicity, secondary amyloidosis, or those which overlap with other autoimmune conditions, are frequently observed in patients with rheumatoid arthritis. This is the first case report of membranous nephropathy in a patient with early-stage rheumatoid arthritis treated with the relatively selective cyclooxygenase-2 inhibitor, etodolac. The present case suggests that any kind of non-steroidal anti-inflammatory drug can cause membranous nephropathy; thus, physicians should be aware of this renal toxicity when prescribing these drugs.
authors.affiliation: Department of Internal Medicine, Shiga University of Medical Science, Otsu. toshiro@belle.shiga-med.ac.jp
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Aoyama
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: Naoko
authors.initials: N
authors.lastname: Deji
authors.forename: Takashi
authors.initials: T
authors.lastname: Uzu
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Nishio
authors.forename: Atsunori
authors.initials: A
authors.lastname: Kashiwagi
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D001707:Biopsy, Needle; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017308:Etodolac / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015433:Glomerulonephritis, Membranous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007677:Kidney Function Tests; D008875:Middle Aged; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D017308:Etodolac